---
title: "DEHUA TB released its performance for the first half of the year, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 9.71%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/253415199.md"
description: "DEHUA TB released its semi-annual report for 2025, with operating revenue of 3.634 billion yuan, a year-on-year decrease of 7.01%; net profit attributable to shareholders was 268 million yuan, a year-on-year increase of 9.71%; net profit excluding non-recurring gains and losses was 238 million yuan, a year-on-year increase of 1.35%. Basic earnings per share were 0.33 yuan, and it plans to distribute a cash dividend of 2.8 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-08-18T08:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253415199.md)
  - [en](https://longbridge.com/en/news/253415199.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253415199.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/253415199.md) | [English](https://longbridge.com/en/news/253415199.md)


# DEHUA TB released its performance for the first half of the year, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 9.71%

According to the Zhitong Finance APP, DEHUA TB (002043.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 3.634 billion yuan, a year-on-year decrease of 7.01%. It realized a net profit attributable to shareholders of the listed company of 268 million yuan, a year-on-year increase of 9.71%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 238 million yuan, a year-on-year increase of 1.35%. The basic earnings per share were 0.33 yuan. It plans to distribute a cash dividend of 2.8 yuan (tax included) for every 10 shares to all shareholders

### 相關股票

- [DEHUA TB (002043.CN)](https://longbridge.com/zh-HK/quote/002043.CN.md)

## 相關資訊與研究

- [Henlius Biotech Gets China Nod for Trial of Lung Cancer Drug](https://longbridge.com/zh-HK/news/279278375.md)
- [VC investors' $200 billion hole: Where did all the money go?](https://longbridge.com/zh-HK/news/278877381.md)
- [Key facts: HSBC eyed for HKMA stablecoin license; Ida Liu heads $566B PB](https://longbridge.com/zh-HK/news/279103566.md)
- [The Naderi Center Introduces Advanced PRF Injections Using the EZPRF Platform](https://longbridge.com/zh-HK/news/278879007.md)
- [DLP Resources Extends Near-Surface Copper Mineralization at Esperanza Project](https://longbridge.com/zh-HK/news/279294992.md)